Phase II genes Keap1/Nrf2/ARE Inducers Effectors Acute neurological diseases Neurodegenerative diseases A B S T R A C T Phase II metabolic enzymes are a battery of critical proteins that detoxify xenobiotics by increasing their hydrophilicity and enhancing their disposal. These enzymes have long been studied for their preventative and protective effects against mutagens and carcinogens and for their regulation via the Keap1 (Kelch-like ECH associated protein 1)/Nrf2 (Nuclear factor erythroid 2 related factor 2)/ARE (antioxidant response elements) pathway. Recently, a series of studies have reported the altered expression of phase II genes in postmortem tissue of patients with various neurological diseases. These observations hint at a role for phase II enzymes in the evolution of such conditions. Furthermore, promising findings reveal that overexpression of phase II genes, either by genetic or chemical approaches, confers neuroprotection in vitro and in vivo. Therefore, there is a need to summarize the current literature on phase II genes in the central nervous system (CNS). This should help guide future studies on phase II genes as therapeutic targets in neurological diseases. In this review, we first briefly introduce the concept of phase I, II and III enzymes, with a special focus on phase II enzymes. We then discuss their expression regulation, their inducers and executors. Following this background, we expand our discussion to the neuroprotective effects of phase II enzymes and the potential application of Nrf2 inducers to the treatment of neurological diseases.
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Abbreviations: Ab, amyloid-beta; AA-MU, alternative activation phenotype; AD, Alzheimer's disease; AhR, aryl hydrocarbon receptor; ALCAR, acetyl-L-carnitine; ALS, amyotrophic lateral sclerosis; ARE, antioxidant response elements; AP-1, activator protein-1; ASK1, apoptosis signal-regulating kinase; BBB, blood brain barrier; BTB, bric-abrac; b-TrCP, beta-transducin repeats-containing proteins; CA-MU, classical activation phenotype; CBP, CREB-binding protein; CDDO, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid; cGMP, cyclic 3 0 ,5 0 -monophosphate; CHD6, chromo-ATPase/helicase DNA binding protein family member 6; CK2, casein kinase 2; CNS, central nervous system; Cul3, Cullin3; D3T, 3H-1,2-dithiole-3-thione; DMEs, drug metabolizing enzymes; DMF, dimethyl fumarate; EAE, experimental autoimmune encephalomyelitis; ERKs, extracellular signal-regulated kinases; EAAC1, excitatory amino acid carrier 1; GCL, g-glutamylcysteine synthetase; Gpx, glutathione peroxidase; GR, glutathione reductase; GST, glutathione s-transferases; GSTP1, glutathione-S-transferase pi 1; GSK-3b, glycogen synthase kinase-3; 6-OHDA, 6-hydroxydopamine; HD, Huntington's Disease; HTT, Huntingtin; HSP32, heat shock protein 32; ICH, intracerebral hemorrhage; MAPK, mitogen-activated protein kinase; MCAO, middle cerebral artery occlusion; MEFs, mouse embryo fibroblasts; MS, multiple sclerosis; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-NP, 3-nitropropionic acid; NES, nuclear export sequence; NLS, nuclear localization signal; Nrf2, nuclear factor erythroid 2 related factor 2; Keap1, Kelch-like ECH associated protein 1; PD, Parkinson's disease; PERK, PKR-like endoplasmic reticulum kinase; ProTa, prothymosina; Prx, peroxiredoxin; PKC, protein kinase C; PI3K, phosphatidylinositol 3-kinase; Rbx1, E3 ubiquitin ligase complex; SAH, subarachnoid hemorrhage; SNpc, substantia nigra pars compacta; Srxn, sulfiredoxin; SFN, sulforaphane; tBHQ, tert-butylhydroquinone; TBI, traumatic brain injury; Trx, thioredoxin; TrxR, Trx reductase; XRE, xenobiotic response element.
